{"name":"Tego Science, Inc.","slug":"tego-science-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TPX-114","genericName":"TPX-114","slug":"tpx-114","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TPX-105","genericName":"TPX-105","slug":"tpx-105","indication":"Neuropathic pain (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"TPX-114","genericName":"TPX-114","slug":"tpx-114","phase":"phase_3","mechanism":"TPX-114 is a small molecule inhibitor of the CDK9 enzyme.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"TPX-105","genericName":"TPX-105","slug":"tpx-105","phase":"phase_3","mechanism":"TPX-105 is a selective inhibitor of transient receptor potential (TRP) channels involved in pain signaling.","indications":["Neuropathic pain (Phase 3)","Chronic pain conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxNR0VjSTdSR3hwVVRCbnZUQ3FtcV9ZbHYxOGRST0x5NkM2Z21UeUNJNk5zcGYzMzM2T3BwLUQ0QVV2b0pZelF5NWVDcTVjaWdrNFZycmxwSHRRT25EWjRhRXVlQzBRVVkyZlBvUnVmYUJxWU5HTEN4bl8yMEZjTEMwc0Y3YWNwSVZrVGpmYmZTdFlCMUdxVGNJVTZySkptYVZEbGI2QTNLcnozWGhSSXdJZHJibFlRYTY0VXdwQnUzbThvTDg1UUZ3MDZja2k0S0d1VEIxaU1jazZUbERPUnVNR0ZVeTV1UHFKOEFPQzZkT3ZObXJsdHVGQ3Bqb3RKLUR4dU1qS1U4ZDdVdkpNUWZSX2w2YnVYWnk0OWRzWGg1QTFTa0EwTVM0ZnNqVlp4RjJSdlY0T05XS0YzZk0?oc=5","date":"2025-11-24","type":"pipeline","source":"prnewswire.com","summary":"Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence - prnewswire.com","headline":"Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Faste","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQX3FwcFhwT1lkVjNiV2VIX1lUM1hTcU5sWGdDS2hsQVhUcXc0QTU2V2YzeG5xTGZkN01QdmF1UHE2d1JMWUdjSGY5Z2Z6RHRfTy1uOVJkVmdKdU1CeXZQUmhtOEVHbjdvUkZoeXE4azh2UGY5Sm1oRi1nSWNwWHoyNGJ4UXdvQk1PNF9sX0lLaGNJOGZHTTZjVVJibFhtTlZxVk1YLXFEZ0VhSHBuLUww?oc=5","date":"2025-02-26","type":"pipeline","source":"BioSpace","summary":"Allogeneic Cell Therapy Market Size to Hit USD 4,677.38 Million by 203 - BioSpace","headline":"Allogeneic Cell Therapy Market Size to Hit USD 4,677.38 Million by 203","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBtRzlVSGN0bjBOMHJvMGMySU9EX2MwZFN4dmNMVU00MFJJWndqRWNDX2N5bENPcDlOQVVEaE1ZYmRMOWh4VzRSRUlUZy1HVGkySHJTRzBicEsxOW1ERGt0TDU4Yi1la2xTNGlyVzRR0gFyQVVfeXFMUFJTdkhMcVRBTTM1aGY4SGNjWlJ1VVYzUTZKcDdRcFJTN09NanRKRk9jSkVVS1U5THZIdFJZLU9McnJWM1dZQzdYUzlrX1pOVGViRlF5M2RXYmV3NWlrR0JPbFpfM2YzQ3pUZ191T3hqTGdB?oc=5","date":"2025-02-17","type":"regulatory","source":"koreabiomed.com","summary":"Tego Science wins FDA nod for phase 2 trial of TPX-115 in rotator cuff tears - koreabiomed.com","headline":"Tego Science wins FDA nod for phase 2 trial of TPX-115 in rotator cuff tears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQaklMZ1JYbWF5VGliVEdlUXhMM0NJTEpvS2hha09UNGtLcEEyTG1udExnX0F4Yi1TUTJXVTRzZzFyajlSOFFTLS1vSWlMYmt1SjFkdFJmOWQzSlBrR0xfejJpYnFmYTlwc1ZEOWVtZzhpXzdPczNEbnlWVXphRjduRHVYZEE3dWJXMVVRbENnaXVjQktXR1E4VUF2MEJ3UWF2?oc=5","date":"2024-03-22","type":"pipeline","source":"BioWorld News","summary":"Eledon takes new ‘tac’ with tegoprubart in kidney transplant - BioWorld News","headline":"Eledon takes new ‘tac’ with tegoprubart in kidney transplant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8tLW1TNnRPVGp5NDhjVE1hckxTQmhoOEZRaVRJUlBNc0E4d0M2RXpfOUI1dkQtRDY1VWl1RjFOUG1la2dhallUUTRKYVhpemtQbUtXVF9yMHZBNzBKUzlJMXJPSDlLQWszUi1iZXl3bVBIWk50RkJWZDZ6N2tuR0k?oc=5","date":"2021-06-24","type":"pipeline","source":"Allied Market Research","summary":"Autologous Cell Therapy Market Size & Share | Report By 2031 - Allied Market Research","headline":"Autologous Cell Therapy Market Size & Share | Report By 2031","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5EZV9mYzBnNExMUDV0ZVBvLV9yOWNETk5IUXN1TnVRLTRiNDlqS0hwaTM3NzR3ZG1yZlVyLTVKM3FQTjhxYnZhd1NzOGhUVV9TamdDNnNrbFA?oc=5","date":"2019-06-15","type":"pipeline","source":"Market.us","summary":"Cell Therapy Market Size, Share | CAGR of 16.7% - Market.us","headline":"Cell Therapy Market Size, Share | CAGR of 16.7%","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}